Die Stallergenes Greer Foundation fördert Innovation und Präzisionsmedizin auf dem Gebiet der Allergien

Stallergenes Greer, ein biopharmazeutisches Unternehmen, das sich auf die Erforschung, Diagnose und Behandlung von Allergien der Atemwege spezialisiert hat, freut sich, seine strategische Ausrichtung für die Stallergenes Greer Foundation bekannt zu geben. Die unter der Schirmherrschaft der Fondation de France…

Read MoreDie Stallergenes Greer Foundation fördert Innovation und Präzisionsmedizin auf dem Gebiet der Allergien

Acuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

Acuamark Diagnostics has appointed Giulia Kennedy, Ph.D., formerly global chief scientific officer and chief medical officer of diagnostics company Veracyte, to its board of directors. “With sharp intellect, deep humanity and decades of in-depth genomic diagnostic development, company building, and commercialization experience, she…

Read MoreAcuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of Directors

GE HealthCare Announces Availability of Next-Generation bkActiv for Guiding Urology, Colorectal and Pelvic Floor Surgeries

GE HealthCare (Nasdaq: GEHC) announced today the next-generation bkActiv is now available for guiding urology, colorectal and pelvic floor surgical procedures. The flagship intraoperative ultrasound imaging system, developed by BK Medical – a subsidiary of GE HealthCare, was designed to…

Read MoreGE HealthCare Announces Availability of Next-Generation bkActiv for Guiding Urology, Colorectal and Pelvic Floor Surgeries

Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year…

Read MoreSurmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Resilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer

A pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announced that National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company, has adopted REBEL at-line media analyzers in their process development to inform and optimize cell culture feed strategies and media design.…

Read MoreResilience Demonstrates Lower Cost of Perfusion Bioreactor Process Using 908 Devices’ REBEL At-line Analyzer

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the company’s…

Read MoreBausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Vektor Medical Welcomes Two New Advisors to Advance Technology and Commercial Development

Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr.…

Read MoreVektor Medical Welcomes Two New Advisors to Advance Technology and Commercial Development

LA FONDATION STALLERGENES GREER SOUTIENT L’INNOVATION ET LA MÉDECINE DE PRÉCISION DANS LE DOMAINE DES ALLERGIES

Stallergenes Greer, laboratoire biopharmaceutique spécialisé dans la recherche, le diagnostic et le traitement des allergies respiratoires, a le plaisir d’annoncer les orientations stratégiques de sa fondation. La Fondation Stallergenes Greer, sous l’égide de la Fondation de France, œuvre à construire…

Read MoreLA FONDATION STALLERGENES GREER SOUTIENT L’INNOVATION ET LA MÉDECINE DE PRÉCISION DANS LE DOMAINE DES ALLERGIES

Stallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy

Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation. The Stallergenes Greer Foundation, under the aegis of the Fondation de France, aims…

Read MoreStallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy

Mawi DNA Technologies erhält 510(k)-Zulassung für “iSWAB-Respiratory Tract Sample Collection Media-Extraction Less” für SARS-CoV-2

Mawi DNA Technologies (Mawi DNA), ein Biotechnologieunternehmen, das sich auf die Entwicklung und das Design innovativer Technologien für die Bioprobenentnahme konzentriert, gibt bekannt, dass die U.S. Food and Drug Administration (FDA) die 510(k)-Zulassung für die “iSWAB-Respiratory Tract Sample Collection Media-Extraction Less™”…

Read MoreMawi DNA Technologies erhält 510(k)-Zulassung für “iSWAB-Respiratory Tract Sample Collection Media-Extraction Less” für SARS-CoV-2